医薬品・バイオテクノロジーにおける流通取引 (2016～2024年)

当レポートでは、世界の医薬品・バイオテクノロジー市場における流通取引の締結情況について分析し、全体的な取引件数の推移や予測 (2016～2024年)、近年の代表的取引の事例、主要企業による取引締結の動き、技術別・治療領域別の契約条件の傾向、といった情報を取りまとめてお届けいたします。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 流通取引の動向

• イントロダクション
• 流通取引の定義
• 流通取引の動向 (2016年以降)
  • 流通取引の動向：年別 (2016～2024年)
  • 流通取引の動向：開発段階別 (2016～2024年)
  • 流通取引の動向：産業分野別 (2016～2024年)
  • 流通取引の動向：治療領域別 (2016～2024年)
  • 流通取引の動向：技術の種類別 (2016～2024年)
  • 流通取引の動向：最も活発な企業の場合 (2016～2024年)
  • 純粋な流通取引の属性
  • マルチコンポーネント取引における流通の属性
• 流通契約の履行のための事業提携の締結

第3章 流通取引の構造：概要

• イントロダクション
• 流通契約の構造
• より広範な提携契約の一部としての販売権

第4章 主要な流通取引

• イントロダクション
• 上位の流通取引 (金額ベース)

第5章 流通取引：最も活発な取引締結企業25社

• イントロダクション
• 流通取引：最も活発な取引締結企業25社

第6章 流通取引：契約の内訳

• イントロダクション
• 流通取引の契約件数 (2016～2024年)
• 取引内訳
• 取引内訳：流通の取引締結、企業名別 (A～Z)
• 取引内訳：流通の取引締結、治療領域別
• 取引内訳：流通の取引締結、技術の種類別

Wildwood Venturesについて

Distribution Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter distribution deals.

Fully revised and updated, the report provides details of distribution deals from 2016 to 2024.

The report provides access to distribution deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of distribution deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of distribution dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of distribution deals.

Chapter 4 provides a review of the leading distribution deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal.

The deal directory includes a comprehensive listing of all distribution deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.

Key benefits

Distribution Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse distribution deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Distribution Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.

Distribution Deals in Pharmaceuticals and Biotechnology includes:

• Trends in distribution dealmaking in the biopharma industry
• Overview of distribution deal structure
• Directory of distribution deal records covering pharmaceutical and biotechnology
• The leading distribution deals by value
• Most active distribution dealmakers
• The leading distribution partnering resources

In Distribution Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Distribution Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for distribution deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in distribution dealmaking

• 2.1. Introduction
• 2.2. Definition of distribution deals
• 2.3. Trends in distribution deals since 2016
  • 2.3.1. Distribution dealmaking by year, 2016 to 2024.
  • 2.3.2. Distribution dealmaking by phase of development, 2016 to 2024.
  • 2.3.3. Distribution dealmaking by industry sector, 2016 to 2024.
  • 2.3.4. Distribution dealmaking by therapy area, 2016 to 2024.
  • 2.3.5. Distribution dealmaking by technology type, 2016 to 2024.
  • 2.3.6. Distribution dealmaking by most active company, 2016 to 2024.
  • 2.3.7. Attributes of pure distribution deals
  • 2.3.8. Attributes of distribution in multi-component deals
• 2.4. Aligning partners to make the distribution agreement workChapter

Chapter 3 - Overview of distribution deal structure

• 3.1. Introduction
• 3.2. Distribution agreement structure
• 3.3. Distribution rights as part of a wider alliance agreement

Chapter 4 - Leading distribution deals

• 4.1. Introduction
• 4.2. Top distribution deals by value

Chapter 5 - Top 25 most active distribution dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active distribution dealmakers

Chapter 6 - Distribution deals including contracts directory

• 6.1. Introduction
• 6.2. Distribution deals with contracts 2016-2024
• Deal directory
• Deal directory - distribution dealmaking by companies A-Z
• Deal directory - distribution dealmaking by therapy area
• Deal directory - distribution dealmaking by technology type

About Wildwood Ventures

• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of distribution
• Figure 2: Trends in distribution deal announcements, 2016 to 2024
• Figure 3: Distribution deals signed at each phase of development, 2016 to 2024
• Figure 4: Distribution deals by industry sector, 2016 to 2024
• Figure 5: Distribution deals by therapy area, 2016 to 2024
• Figure 6: Distribution deals by technology type, 2016 to 2024
• Figure 7: Top 25 most active distribution dealmakers, 2016 to 2024
• Figure 8: Issues in implementing distribution agreements
• Figure 9: Distribution agreements - what should a contract include?
• Figure 10: Components of the distribution deal structure
• Figure 11: Top distribution deals by value 2016 to 2024
• Figure 12: Most active distribution dealmakers 2016 to 2024